OA12350A - Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors. - Google Patents
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors. Download PDFInfo
- Publication number
- OA12350A OA12350A OA1200300022A OA1200300022A OA12350A OA 12350 A OA12350 A OA 12350A OA 1200300022 A OA1200300022 A OA 1200300022A OA 1200300022 A OA1200300022 A OA 1200300022A OA 12350 A OA12350 A OA 12350A
- Authority
- OA
- OAPI
- Prior art keywords
- substituted
- alkyl
- chain
- mono
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22327900P | 2000-08-03 | 2000-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12350A true OA12350A (en) | 2006-05-16 |
Family
ID=22835821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200300022A OA12350A (en) | 2000-08-03 | 2001-07-31 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors. |
Country Status (39)
Country | Link |
---|---|
US (4) | US7115279B2 (is) |
EP (2) | EP2258352B1 (is) |
JP (2) | JP2004505911A (is) |
KR (1) | KR100561572B1 (is) |
CN (1) | CN1458840A (is) |
AP (1) | AP2001002235A0 (is) |
AR (1) | AR030570A1 (is) |
AT (1) | ATE503462T1 (is) |
AU (1) | AU2914202A (is) |
BG (1) | BG107456A (is) |
BR (1) | BR0112828A (is) |
CA (1) | CA2417755A1 (is) |
CR (1) | CR6883A (is) |
CZ (1) | CZ2003224A3 (is) |
DE (1) | DE60144332D1 (is) |
DO (1) | DOP2001000224A (is) |
DZ (1) | DZ3391A1 (is) |
EA (1) | EA007013B1 (is) |
EC (1) | ECSP034462A (is) |
EE (1) | EE200300052A (is) |
GT (1) | GT200100156A (is) |
HN (1) | HN2001000175A (is) |
HU (1) | HUP0300676A2 (is) |
IL (1) | IL154017A0 (is) |
IS (1) | IS6688A (is) |
MA (1) | MA26935A1 (is) |
MX (1) | MXPA03001035A (is) |
NO (1) | NO20030506L (is) |
NZ (1) | NZ523680A (is) |
OA (1) | OA12350A (is) |
PA (1) | PA8523901A1 (is) |
PE (1) | PE20020271A1 (is) |
PL (1) | PL365168A1 (is) |
SK (1) | SK1032003A3 (is) |
SV (1) | SV2002000581A (is) |
TN (1) | TNSN01119A1 (is) |
UY (1) | UY26864A1 (is) |
WO (1) | WO2002011710A2 (is) |
ZA (1) | ZA200300869B (is) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
DE10063486A1 (de) * | 2000-12-20 | 2002-07-04 | Bayer Ag | Dichlorpyridylmethylamide |
BR0210505A (pt) * | 2001-06-21 | 2004-05-18 | Pfizer Prod Inc | Formulações auto-emulsionantes de inibidores da proteìna de transferência de ésteres de colesterilo |
BR0210519A (pt) * | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de adsorvatos de fármaco amorfo |
EP1401503B1 (en) * | 2001-06-22 | 2007-05-09 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer |
ATE480226T1 (de) * | 2001-06-22 | 2010-09-15 | Bend Res Inc | Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere |
DE60233874D1 (de) * | 2001-06-22 | 2009-11-12 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
AU2002309172A1 (en) * | 2001-06-22 | 2003-01-08 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
BR0307344A (pt) * | 2002-02-01 | 2004-12-14 | Pfizer Prod Inc | Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica |
AR038375A1 (es) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
BR0307515A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
ES2309294T3 (es) | 2002-02-01 | 2008-12-16 | Pfizer Products Inc. | Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferecncia de ester de colesterilo. |
RU2004123621A (ru) | 2002-02-01 | 2005-04-10 | Пфайзер Продактс Инк. (Us) | Лекарственные формы с немедленным высвобождением, содержащие твердые дисперсии лекарств |
PT1469833T (pt) | 2002-02-01 | 2021-07-13 | Bend Res Inc | Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado |
RU2005103625A (ru) * | 2002-08-12 | 2005-08-20 | Пфайзер Продактс Инк. (Us) | Фармацевтические композиции полуупорядоченных лекарств и полимеров |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
BR0315041A (pt) | 2002-10-04 | 2005-08-16 | Millennium Pharm Inc | Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica |
JP2006512359A (ja) * | 2002-12-20 | 2006-04-13 | ファイザー・プロダクツ・インク | CETP阻害薬及びHMG−CoA還元酵素阻害薬を含有する剤形 |
AU2003283769A1 (en) * | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
AU2004222436A1 (en) * | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate |
ZA200508160B (en) * | 2003-03-17 | 2007-01-31 | Japan Tobacco Inc | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl) 2-methyl-propanethioate |
MXPA05009848A (es) | 2003-03-17 | 2005-12-06 | Japan Tobacco Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo. |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
WO2005011634A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
WO2005011635A2 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
WO2005030185A2 (en) * | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Method of inhibiting remnant lipoprotein production |
EP1670765A2 (en) * | 2003-09-30 | 2006-06-21 | Pfizer Products Inc. | Cetp inhibitors and metabolites thereof |
KR20060085675A (ko) * | 2003-10-08 | 2006-07-27 | 일라이 릴리 앤드 캄파니 | 이상지혈증 치료를 위한 화합물 및 방법 |
PL1759702T3 (pl) * | 2004-05-26 | 2009-06-30 | Bayardo Arturo Jimenez | Sposób wytwarzania roztworu latanoprostu do oczu oraz roztwór otrzymany tym sposobem |
US7700774B2 (en) | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
KR101238525B1 (ko) | 2004-12-31 | 2013-02-28 | 레디 유에스 테라퓨틱스 인코포레이티드 | Cetp 저해제로서의 신규 벤질아민 유도체 |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
EP1845953A1 (en) * | 2005-02-03 | 2007-10-24 | Pfizer Products Incorporated | Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
ZA200707498B (en) | 2005-02-24 | 2008-11-26 | Millennium Pharm Inc | PGD2 receptor antagonists for the treatment of inflammatory diseases |
EP1942872A2 (en) * | 2005-11-04 | 2008-07-16 | Eastman Chemical Company | Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents |
NZ569700A (en) * | 2006-02-09 | 2011-09-30 | Merck Sharp & Dohme | Polymer formulations of CETP inhibitors |
PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
EP1997819A1 (de) | 2007-05-25 | 2008-12-03 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Herstellung von Scopinestern |
US8337835B2 (en) * | 2009-04-10 | 2012-12-25 | Washington University | Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders |
WO2010147978A1 (en) | 2009-06-16 | 2010-12-23 | Pfizer Inc. | Dosage forms of apixaban |
EP2675434A1 (en) | 2011-02-17 | 2013-12-25 | F.Hoffmann-La Roche Ag | A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion |
WO2012122279A1 (en) | 2011-03-08 | 2012-09-13 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
CA2845284C (en) | 2011-08-18 | 2018-03-06 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors |
KR101803866B1 (ko) | 2011-09-27 | 2017-12-04 | 닥터 레디스 레보러터리즈 리미티드 | 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체 |
RU2015123632A (ru) * | 2012-11-19 | 2017-01-10 | Др. Редди'С Лабораторис Лтд. | Фармацевтические композиции ингибиторов сетр |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3871866D1 (de) | 1987-07-17 | 1992-07-16 | Dow Corning | Haertbare zusammensetzung. |
JP2528706B2 (ja) * | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
US5093371A (en) * | 1990-07-02 | 1992-03-03 | University Of Iowa Research Foundation | Naphthyl ketone inhibitors of cholesterol esterase and their use as hypolipidemic and hypocaloric agents |
ATE159426T1 (de) | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
US5446207A (en) * | 1993-09-01 | 1995-08-29 | Harbor Branch Oceanographic Institution, Inc. | Anti-dyslipidemic agents |
US5474993A (en) * | 1994-06-14 | 1995-12-12 | Sterling Winthrop, Inc. | Lactam inhibitors of cholesterol esterase |
WO1996015141A1 (en) | 1994-11-12 | 1996-05-23 | Lg Chemical Ltd. | Cholesteryl ester transfer protein inhibitor peptides and prophylactic and therapeutic anti-arteriosclerosis agents |
WO1996019239A1 (fr) * | 1994-12-21 | 1996-06-27 | Yamanouchi Pharmaceutical Co., Ltd. | Composition solide a solubilite et absorbabilite ameliorees |
TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
GB2305665A (en) * | 1995-09-26 | 1997-04-16 | Merck & Co Inc | Selective ß3 agonists for the treatment of diabetes aand obesity |
DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
JP3290962B2 (ja) * | 1997-02-12 | 2002-06-10 | 日本たばこ産業株式会社 | Cetp活性阻害剤 |
DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
JPH10287662A (ja) | 1997-04-08 | 1998-10-27 | Kitasato Inst:The | Fo−5637a物質及びb物質並びにそれらの製造法 |
EP0975617B1 (en) * | 1997-04-16 | 2003-11-05 | The University of New Mexico | Inhibitors of cholesterol esterase |
US5955475A (en) * | 1997-06-30 | 1999-09-21 | Endo Pharmaceuticals Inc. | Process for manufacturing paroxetine solid dispersions |
EP0901786B1 (en) * | 1997-08-11 | 2007-06-13 | Pfizer Products Inc. | Solid pharmaceutical dispersions with enhanced bioavailability |
AU9297798A (en) | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
MA24643A1 (fr) | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
AU3285499A (en) | 1998-02-13 | 1999-08-30 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
JP3433417B2 (ja) * | 1998-04-02 | 2003-08-04 | トヨタ自動車株式会社 | レーダ装置 |
BR9910481A (pt) * | 1998-06-11 | 2001-01-09 | Upjohn Co | Composição farmacêutica para comprimido de liberação não-contìnua |
US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
CA2345108A1 (en) | 1998-09-25 | 2000-04-06 | Monsanto Company | Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
JP3955180B2 (ja) | 1998-09-25 | 2007-08-08 | ファルマシア・コーポレーション | コレステリルエステル伝達タンパク質活性を阻害するのに有用な(R)−キラルなハロゲン化された1−置換アミノ−(n+1)−アルカノール |
ES2307482T3 (es) * | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
AU751849B2 (en) | 1999-03-08 | 2002-08-29 | Kitasato Institute, The | Substances WK-5344A and WK-5344B and process for producing the same |
US6465011B2 (en) | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US20010018446A1 (en) | 1999-09-23 | 2001-08-30 | G.D. Searle & Co. | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
CO5271716A1 (es) | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
JP4100910B2 (ja) * | 1999-12-23 | 2008-06-11 | ファイザー・プロダクツ・インク | ヒドロゲル駆動の薬物剤形 |
WO2001056579A1 (en) | 2000-02-04 | 2001-08-09 | Esperion Therapeutics Inc. | Methods for treating alzheimer's disease |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
DE60233874D1 (de) * | 2001-06-22 | 2009-11-12 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
AU2002309172A1 (en) * | 2001-06-22 | 2003-01-08 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
ATE480226T1 (de) * | 2001-06-22 | 2010-09-15 | Bend Res Inc | Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere |
PT1469833T (pt) * | 2002-02-01 | 2021-07-13 | Bend Res Inc | Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado |
AR038375A1 (es) * | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
JP2006512359A (ja) * | 2002-12-20 | 2006-04-13 | ファイザー・プロダクツ・インク | CETP阻害薬及びHMG−CoA還元酵素阻害薬を含有する剤形 |
-
2001
- 2001-07-30 US US09/918,127 patent/US7115279B2/en not_active Expired - Fee Related
- 2001-07-31 OA OA1200300022A patent/OA12350A/en unknown
- 2001-07-31 EE EEP200300052A patent/EE200300052A/xx unknown
- 2001-07-31 IL IL15401701A patent/IL154017A0/xx unknown
- 2001-07-31 EA EA200300073A patent/EA007013B1/ru not_active IP Right Cessation
- 2001-07-31 SK SK103-2003A patent/SK1032003A3/sk not_active Application Discontinuation
- 2001-07-31 WO PCT/IB2001/001391 patent/WO2002011710A2/en active IP Right Grant
- 2001-07-31 EP EP20100180614 patent/EP2258352B1/en not_active Expired - Lifetime
- 2001-07-31 CA CA002417755A patent/CA2417755A1/en not_active Abandoned
- 2001-07-31 CZ CZ2003224A patent/CZ2003224A3/cs unknown
- 2001-07-31 JP JP2002517047A patent/JP2004505911A/ja active Pending
- 2001-07-31 DE DE60144332T patent/DE60144332D1/de not_active Expired - Lifetime
- 2001-07-31 NZ NZ523680A patent/NZ523680A/en unknown
- 2001-07-31 CN CN01815834A patent/CN1458840A/zh active Pending
- 2001-07-31 BR BR0112828-0A patent/BR0112828A/pt not_active IP Right Cessation
- 2001-07-31 AT AT01984472T patent/ATE503462T1/de not_active IP Right Cessation
- 2001-07-31 KR KR1020037001456A patent/KR100561572B1/ko not_active IP Right Cessation
- 2001-07-31 DZ DZ013391A patent/DZ3391A1/xx active
- 2001-07-31 EP EP01984472A patent/EP1305007B1/en not_active Expired - Lifetime
- 2001-07-31 HU HU0300676A patent/HUP0300676A2/hu unknown
- 2001-07-31 SV SV2001000581A patent/SV2002000581A/es not_active Application Discontinuation
- 2001-07-31 AU AU2914202A patent/AU2914202A/xx not_active Withdrawn
- 2001-07-31 MX MXPA03001035A patent/MXPA03001035A/es active IP Right Grant
- 2001-07-31 PL PL01365168A patent/PL365168A1/xx unknown
- 2001-08-01 DO DO2001P000224A patent/DOP2001000224A/es unknown
- 2001-08-01 GT GT200100156A patent/GT200100156A/es unknown
- 2001-08-01 UY UY26864A patent/UY26864A1/es not_active Application Discontinuation
- 2001-08-02 AP APAP/P/2001/002235A patent/AP2001002235A0/en unknown
- 2001-08-02 TN TNTNSN01119A patent/TNSN01119A1/fr unknown
- 2001-08-02 AR ARP010103694A patent/AR030570A1/es unknown
- 2001-08-02 PE PE2001000773A patent/PE20020271A1/es not_active Application Discontinuation
- 2001-08-03 PA PA20018523901A patent/PA8523901A1/es unknown
- 2001-08-06 HN HN2001000175A patent/HN2001000175A/es unknown
-
2003
- 2003-01-13 BG BG107456A patent/BG107456A/bg unknown
- 2003-01-16 CR CR6883A patent/CR6883A/es not_active Application Discontinuation
- 2003-01-16 IS IS6688A patent/IS6688A/is unknown
- 2003-01-23 MA MA27010A patent/MA26935A1/fr unknown
- 2003-01-31 ZA ZA200300869A patent/ZA200300869B/en unknown
- 2003-01-31 NO NO20030506A patent/NO20030506L/no not_active Application Discontinuation
- 2003-02-03 EC EC2003004462A patent/ECSP034462A/es unknown
-
2006
- 2006-06-02 US US11/421,888 patent/US8048452B2/en not_active Expired - Fee Related
-
2007
- 2007-04-30 US US11/799,447 patent/US8197848B2/en not_active Expired - Fee Related
- 2007-08-09 JP JP2007208058A patent/JP2007314573A/ja active Pending
-
2012
- 2012-06-12 US US13/494,668 patent/US8389011B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA12350A (en) | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors. | |
CA2448864C (en) | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer | |
AU2002302903B9 (en) | Pharmaceutical compositions of adsorbates of amorphous drug | |
OA12624A (en) | Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers. | |
WO2003000235A1 (en) | Pharmaceutical compositions of dispersions of drugs and neutral polymers | |
CA2450748A1 (en) | Pharmaceutical compositions containing polymer and drug assemblies | |
AU2002302903A1 (en) | Pharmaceutical compositions of adsorbates of amorphous drug | |
CA2474447A1 (en) | Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors | |
AU2002229142B2 (en) | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | |
AU2002229142A1 (en) | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | |
AU2002302886A1 (en) | Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers |